Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer

References

• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899.
   PubMed Web of Science ®Google Scholar
• Viola D, Valerio L, Molinaro E, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23:R185–R205.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015;20:176.
   Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–328.
   PubMed Web of Science ®Google Scholar
• Gallo M, Michelon F, Castiglione A, et al. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine. 2015;49:726–734.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Eng J Med. 2015;372:621–630.
   PubMed Web of Science ®Google Scholar
• Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014;99:2086–2094.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03 2010. Accessed 2017 Aug 01 Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Oudard S, Geoffrois L, Guillot A, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma - results of the rechallenge with sunitinib in metastatic RCC (RESUME) study. Eur J Cancer. 2016;62:28–35.
   PubMed Web of Science ®Google Scholar
• Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116:5400–5406.
   PubMed Web of Science ®Google Scholar
• Grünwald V, Weikert S, Seidel C, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34:310–314.
   PubMedGoogle Scholar
• Nagyivanyi K, Biro K, Gyergyay F, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Ann Oncol. 2012;23(abs):849P.
   Google Scholar
• Porta C, Paglino C, Grünwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014;111:1047–1053.
   PubMed Web of Science ®Google Scholar
• Shablak A, O’Dwyer J, Hawkins R, et al. Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases. Urol Int. 2011;86(2):245–248.
   PubMed Web of Science ®Google Scholar
• Paule B, Brion N. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus. Anticancer Res. 2011;31:3507–3510.
   PubMed Web of Science ®Google Scholar
• Nozawa M, Yamamoto Y, Minami T, et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. Br J Urol Int. 2012;110:E228–E234.
   Google Scholar
• Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175–1182.
   PubMed Web of Science ®Google Scholar
• Italiano A, Cioffi A, Coco P, et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol. 2012;19:1551–1559.
   PubMed Web of Science ®Google Scholar
• Sawaki A, Kanda T, Komatsu Y, et al. Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib. Gastroenterol Res Pract. 2014;2014:342986.
   PubMedGoogle Scholar
• Fumagalli E, Coco P, Morosi C, et al. Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy. J Clin Oncol. 2010;28(abstr):e20519.
   Google Scholar
• Yokouchi H, Yamazaki K, Kinoshita I, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer. 2007 20;7:51.
   PubMed Web of Science ®Google Scholar
• Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res. 2005;15:107–111.
   PubMed Web of Science ®Google Scholar
• Kurata T, Tamura K, Kaneda H, et al. Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance. Ann Oncol. 2004;15:173–174.
   PubMed Web of Science ®Google Scholar
• Yoshimoto A, Inuzuka K, Kita T, et al. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci. 2007;333:221–225.
   PubMed Web of Science ®Google Scholar
• Marotta V, Colao A, Faggiano A. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine. 2015;50:824–825.
   PubMed Web of Science ®Google Scholar
• Bielecka ZF, Czarnecka AM, Solarek W, et al. Mechanisms of acquired resistance to Tyrosine Kinase inhibitors in clear - cell renal cell carcinoma (ccRCC). Curr Signal Transduct Ther. 2014;8:218–228.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev. 2012;38:996–1003.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Goldberg SN, et al. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011;9:220.
   PubMed Web of Science ®Google Scholar
• Zhang L, Bhasin M, Schor-Bardach R, et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 29;6:e19144.
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9:1525–1535.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012;109:E2127–33.
   PubMed Web of Science ®Google Scholar
• Stein B, Smith BD. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010;32:804–820.
   PubMed Web of Science ®Google Scholar